The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD)

Journal of Japanese Society of Gastroenterology

Volumn 108, Issue 8, 2011, Pages 1383-1392

  Shiwa, Tadashi ^a   Kawanami, Yoshiya ^a   Yokoyama, Tomoko ^a   Moritani, Akihiko ^a   Hashimoto, Masatoshi ^a   Gotoh, Tohru ^b  

^a Fujifilm Health Care Center   (Japan)

^b Omori Red Cross Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EZETIMIBE;

ARTICLE; DYSLIPIDEMIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; NONALCOHOLIC FATTY LIVER; ULTRASOUND;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 80052428505     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kubo M., Kiyohara Y., Kato I., et al : Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community : the Hisayama study. Stroke 34; 2349-2354 : 2003
2. Kojima S., Watanabe N., Numata M., et al : Increase in the prevalence of fatty liver in Japan over the past 12 years : analysis of clinical background. J Gastroenterol 38; 954-561 : 2003
3. Hamaguchi M., Kojima T., Itoh Y., et al : The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102; 2708-2715 : 2007
4. Omagari K., Morikawa S., Nagaoka S., et al : Predictive factors for the development or regression of Fatty liver in Japanese adults. J Clin Biochem Nutr 45; 56-67 : 2009
5. Hamaguchi M., Kojima T., Takeda N., et al : Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13; 1579-1584 : 2007
6. Ekstedt M., Franzén L.E., Mathiesen U.L., et al : Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44; 865-873 : 2006
7. Targher G., Arcaro G. : Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191; 235-240 : 2007
8. Musso G., Gambino R., Cassader M., et al : A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52; 79-104 : 2010
9. Progress in Medicine 27; 157-162 : 2007
10. Deushi M., Nomura M., Kawakami A., et al : Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581; 5664-5670 : 2007
11. Progress in Medicine 28; 1769-1775 : 2008
12. Nozaki Y., Fujita K., Yoneda M., et al : Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 51; 548-556 : 2009
13. Yoneda M., Fujita K., Nozaki Y., et al : Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis : An open-label pilot study. Hepatol Res 40; 613-621 : 2010
14. Davies J.P., Scott C., Oishi K., et al : Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia J Biol Chem 280; 12710-12720 : 2005
15. Yamagishi S., Nakamura K., Matsui T., et al : Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med Hypotheses 66; 844-846 : 2006
16. Assy N., Grozovski M., Bersudsky I., et al : Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with nonalcoholic fatty liver disease. World J Gastroenterol 12; 4369-1376 : 2006
17. Joseph A.E., Saverymuttu S.H., al-Sam S., et al : Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43; 26-31 : 1991
18. Williams C.D., Stengel J., Asike M.I., et al : Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy : A prospective study. Gastroenterology 140; 124-131 : 2011
19. Altmann S.W., Davis H.R. Jr, Zhu L.J., et al : Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303; 1201-1204 : 2004
20. Temel R.E., Tang W., Ma Y., et al : Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117; 1968-1978 : 2007
21. Muraoka T., Aoki K., Iwasaki T., et al : Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 60; 617-628 : 2011
22. Marchesini G., Brizi M., Bianchi G., et al : Nonalcoholic fatty liver disease : a feature of the metabolic syndrome. Diabetes 50; 1844-1850 : 2001